1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow vobramitamab duocarmazine 2.7 mg (Arm B): new trials by email Literature Review of vobramitamab duocarmazine 2.7 mg (Arm B) trials Research Report on vobramitamab duocarmazine 2.7 mg (Arm B)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
Anus Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Melanoma (1) · Prostatic Neoplasms, Castration-Resistant (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
MacroGenics (1)
Australia (1) · Belgium (1) · France (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)